Florence, November 4, 2024
Hospitex is proud to acknowledge the newly launched collaboration between Ikonisys SA and SYNLAB Italy for the deployment of the Ikoniscope platform in pathology laboratories across the country. As a longstanding partner of Ikonisys in Italy, Hospitex enthusiastically supports this milestone, which represents a concrete step forward in advancing the quality and precision of diagnostic services for oncology and virology.
SYNLAB Italy, part of the SYNLAB Group and a leader in medical diagnostic services throughout Europe, has chosen to integrate the Ikoniscope, Ikonisys’ fully automated platform based on fluorescence in situ hybridization (FISH), into its diagnostic workflow. This cutting-edge system offers high-throughput, high-accuracy cell analysis, enabling early detection of cancer and a more precise understanding of patients’ genetic profiles—essential tools for personalized therapies.
“At Hospitex, we have always believed in the transformative power of advanced diagnostics. Ikonisys’ collaboration with SYNLAB Italy is a clear signal that the future of pathology lies in automation, precision, and personalization. We are proud to support the deployment and growth of Ikonisys technologies in Italy,” said the Hospitex Management Team.
A Turning Point for Italian Pathology Labs
The Ikoniscope is designed to analyze tumor cells with exceptional precision, enabling the detection of specific genetic alterations that are key to both early diagnosis and the development of targeted cancer treatments. For SYNLAB, the addition of the Ikoniscope translates into greater efficiency, the ability to handle growing volumes of testing, and a significant enhancement in diagnostic accuracy—all while offering a better standard of care to patients.
This synergy aligns with Hospitex’s mission: to support innovation and bring cutting-edge technologies into Italian laboratories—empowering healthcare professionals with the tools they need to improve patient outcomes.
Driving Innovation in HPV Testing
The integration of Ikonisys’ technology into SYNLAB’s laboratories also opens new possibilities for HPV diagnostics, particularly in the detection of ASCUS and LSIL lesions. These cell anomalies, often subtle and difficult to classify, can now be more reliably identified and assessed using the Ikoniscope’s advanced imaging and analysis capabilities. This is especially critical in determining the risk of progression toward more serious cervical pathologies, and thus in enabling early, more effective interventions.
A Shared Vision for the Future
At Hospitex, we view this collaboration as a demonstration of the shared commitment among industry leaders—Ikonisys, SYNLAB, and ourselves—to raise the standards of care in Italy. Together, we are contributing to a new era in laboratory medicine, one that places technology and precision at the heart of diagnostics.
